Search

Your search keyword '"Loots DT"' showing total 69 results

Search Constraints

Start Over You searched for: Author "Loots DT" Remove constraint Author: "Loots DT"
69 results on '"Loots DT"'

Search Results

3. Protocol for unified metabolomics and proteomics analysis of formalin-fixed paraffin-embedded tissue.

4. The effect of Tyloxapol on the metabolome of Mycobacterium tuberculosis.

5. Urinary drug metabolite profiling of tuberculosis treatment failure using proton nuclear magnetic resonance.

6. The diagnostic potential of urine in paediatric patients undergoing initial treatment for tuberculous meningitis.

7. Characterizing poorly controlled type 2 diabetes using 1 H-NMR metabolomics.

8. 1 H-NMR metabolomics investigation of CSF from children with HIV reveals altered neuroenergetics due to persistent immune activation.

9. Urinary metabolic characterization of advanced tuberculous meningitis cases in a South African paediatric population.

10. Urinary markers of Mycobacterium tuberculosis and dysbiosis in paediatric tuberculous meningitis cases undergoing treatment.

11. An exploratory investigation of the CSF metabolic profile of HIV in a South African paediatric cohort using GCxGC-TOF/MS.

12. Medicinal Plants against Viral Infections: A Review of Metabolomics Evidence for the Antiviral Properties and Potentials in Plant Sources.

13. The metabolic consequences of HIV/TB co-infection.

14. Tuberculosis is associated with sputum metabolome variations, irrespective of patient sex or HIV status: an untargeted GCxGC-TOFMS study.

15. The metabolic recovery of marathon runners: an untargeted 1 H-NMR metabolomics perspective.

16. The metabolomics of a protein kinase C delta (PKCδ) knock-out mouse model.

17. M. tuberculosis curli pili (MTP) facilitates a reduction of microbicidal activity of infected THP-1 macrophages during early stages of infection.

18. In Silico Drug Discovery Strategies Identified ADMET Properties of Decoquinate RMB041 and Its Potential Drug Targets against Mycobacterium tuberculosis.

19. Tuberculous Granuloma: Emerging Insights From Proteomics and Metabolomics.

20. n -3 long-chain PUFA promote antibacterial and inflammation-resolving effects in Mycobacterium tuberculosis -infected C3HeB/FeJ mice, dependent on fatty acid status.

21. Immune Dysregulation Is Associated with Neurodevelopment and Neurocognitive Performance in HIV Pediatric Populations-A Scoping Review.

22. Beetroot juice - a suitable post-marathon metabolic recovery supplement?

23. Characterizing Marathon-Induced Metabolic Changes Using 1 H-NMR Metabolomics.

24. Adjunct n-3 Long-Chain Polyunsaturated Fatty Acid Treatment in Tuberculosis Reduces Inflammation and Improves Anemia of Infection More in C3HeB/FeJ Mice With Low n-3 Fatty Acid Status Than Sufficient n-3 Fatty Acid Status.

25. Chronological Metabolic Response to Intensive Phase TB Therapy in Patients with Cured and Failed Treatment Outcomes.

26. Elucidating the Antimycobacterial Mechanism of Action of Decoquinate Derivative RMB041 Using Metabolomics.

27. Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

28. Genome Sequence Resource of Pseudomonas fulva HARBPS9.1-Candidate Biocontrol Agent.

29. M. tuberculosis curli pili (MTP) is associated with alterations in carbon, fatty acid and amino acid metabolism in a THP-1 macrophage infection model.

30. Longer-Term Omega-3 LCPUFA More Effective Adjunct Therapy for Tuberculosis Than Ibuprofen in a C3HeB/FeJ Tuberculosis Mouse Model.

31. Metabolic characterization of tuberculous meningitis in a South African paediatric population using 1 H NMR metabolomics.

32. Mycobacterium tuberculosis curli pili (MTP) is associated with significant host metabolic pathways in an A549 epithelial cell infection model and contributes to the pathogenicity of Mycobacterium tuberculosis.

33. Mycobacterium tuberculosis curli pili (MTP) deficiency is associated with alterations in cell wall biogenesis, fatty acid metabolism and amino acid synthesis.

34. The unaided recovery of marathon-induced serum metabolome alterations.

35. Serum Metabolome Changes in Relation to Prothrombotic State Induced by Combined Oral Contraceptives with Drospirenone and Ethinylestradiol.

36. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.

37. Overview of Brain-to-Gut Axis Exposed to Chronic CNS Bacterial Infection(s) and a Predictive Urinary Metabolic Profile of a Brain Infected by Mycobacterium tuberculosis .

38. Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin.

39. Tween 80 induces a carbon flux rerouting in Mycobacterium tuberculosis.

40. Metabolomic applications for understanding complex tripartite plant-microbes interactions: Strategies and perspectives.

41. Time-Dependent Changes in Urinary Metabolome Before and After Intensive Phase Tuberculosis Therapy: A Pharmacometabolomics Study.

42. Bacillus velezensis: phylogeny, useful applications, and avenues for exploitation.

43. The application of metabolomics toward pulmonary tuberculosis research.

44. Total Metabolome Extraction from Mycobacterial Cells for GC-MS Metabolomics Analysis.

45. Fatty Acid Metabolome Extraction from Mycobacterial Cells for GC-MS Metabolomics Analysis.

46. The altered human serum metabolome induced by a marathon.

47. Novel insights into the pharmacometabonomics of first-line tuberculosis drugs relating to metabolism, mechanism of action and drug-resistance.

48. Metabolomics of colistin methanesulfonate treated Mycobacterium tuberculosis.

49. Elucidating the antimicrobial mechanisms of colistin sulfate on Mycobacterium tuberculosis using metabolomics.

50. The cross-tissue metabolic response of abalone ( Haliotis midae ) to functional hypoxia.

Catalog

Books, media, physical & digital resources